Key Takeaways
- BofA Securities upgraded Candel Therapeutics Inc. ($CADL) to 'buy' from 'neutral,' raising its price target to $4.00.
- Candel Therapeutics shares surged 9.3% in premarket trading, extending gains to close up 13.5% at $2.42.
- The upgrade signals increased analyst confidence in $CADL's oncology pipeline, particularly [$CAN](/crypto/channels)-2409's potential in pancreatic cancer.
- Elevated trading volume, reaching over 4.5 million shares, significantly outpaced the 30-day average of 850,000 shares.
- Investors are now monitoring upcoming clinical trial readouts and the company's cash runway for sustained momentum.
Candel Therapeutics Surges on BofA's Bullish Outlook
Candel Therapeutics Inc. ($CADL) shares recorded a substantial rally, closing up 13.5% at $2.42 on Tuesday, following an upgrade by BofA Securities. The investment bank raised its rating on the clinical-stage biotechnology company to 'buy' from 'neutral,' simultaneously increasing its 12-month price target to $4.00 per share from a previous $2.50. This revised outlook reflects heightened confidence in the company's pipeline assets and strategic direction.
The announcement triggered an immediate positive reaction, with $CADL shares initially surging 9.3% in premarket trading to $2.35. The momentum carried into the regular session, pushing the stock to an intraday high of $2.50 before settling slightly lower. This significant price movement indicates a strong shift in investor sentiment, driven by the perceived validation from a major institutional analyst.
Market Impact
Candel Therapeutics' stock experienced its largest single-day percentage gain since March 15, 2023, when it climbed 18.2%. Tuesday's closing price of $2.42 marks the highest level for $CADL since late April, reversing a downtrend that had seen the stock trade below $2.00 for much of the past two months. The company's market capitalization expanded by approximately $15 million, reaching $126 million by the close of trading.
Trading volume for $CADL soared, with over 4.5 million shares changing hands, a more than five-fold increase compared to its 30-day average daily volume of 850,000 shares. This surge in liquidity suggests broad market participation beyond typical institutional trading. While Candel Therapeutics is a small-cap biotech, its robust performance contributed to a positive sentiment ripple across the broader oncology sector, with the $IBB (iShares Biotechnology ETF) rising 0.8% and the $XBI (SPDR S&P Biotech ETF) gaining 1.1% on the same day.
What Analysts Are Saying
BofA Securities analyst Tazeen Ahmad highlighted Candel's lead investigational asset, $CAN-2409, as a primary driver for the upgrade. "Our upgraded rating reflects increasing confidence in $CAN-2409's potential, particularly following encouraging data in pancreatic ductal adenocarcinoma (PDAC) presented at ASCO 2024," Ahmad wrote in a client note. The analyst projected peak sales potential for $CAN-2409 exceeding $1 billion annually if approved for multiple indications, including PDAC and non-small cell lung cancer (NSCLC).
Meanwhile, analysts at Oppenheimer maintained their 'outperform' rating on $CADL, reiterating their $5.00 price target. "Candel's novel viral immunotherapy platform continues to demonstrate promising efficacy and a favorable safety profile across its clinical programs," Oppenheimer stated. They emphasized the company's strategic collaborations and the potential for $CAN-3110 in recurrent glioblastoma to provide additional upside following its Phase 1 data readout.
However, not all perspectives are uniformly bullish. A recent report from Cantor Fitzgerald, which maintains a 'neutral' rating and a $2.50 price target, cautioned on the inherent risks associated with early-stage clinical development. "While $CAN-2409 shows promise, the path to FDA approval for any oncology therapeutic is fraught with challenges, including competitive landscapes and potential trial setbacks," a Cantor Fitzgerald analyst noted. This perspective underscores the speculative nature of biotech investing, particularly for companies without commercialized products.
What to Watch
Investors will be closely monitoring several key developments for Candel Therapeutics in the coming quarters. A critical catalyst will be the anticipated readout of updated clinical data for $CAN-2409 in combination with valacyclovir in PDAC patients, expected by late Q4 2024 or early Q1 2025. Positive results could further de-risk the program and potentially trigger additional institutional interest.
The company's cash runway is another important factor; Candel reported approximately $65 million in cash and equivalents as of March 31, 2024, which is projected to fund operations into the first half of 2025. Any strategic financing activities or partnership announcements will be scrutinized for their impact on dilution and operational longevity. Key technical levels to watch include immediate resistance at $2.60, followed by a more significant barrier at $3.00, representing prior highs from Q1 2024.
On the downside, the $2.20 level could act as immediate support, with stronger support at $2.00. A break below $2.00 could signal a loss of the recent upward momentum. Upcoming scientific presentations, such as at the European Society for Medical Oncology (ESMO) Congress in October, could also provide new data or insights that influence investor sentiment and share price trajectory.
